Skip to main
ABBV
ABBV logo

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 17%
Buy 56%
Hold 28%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie has demonstrated a robust financial outlook, highlighted by management's upward revision of FY 2025 non-GAAP EPS guidance to $12.09-$12.29, reflecting an increase of 10 cents from previous estimates. Additionally, the company has revised its revenue forecast for FY 2025 to approximately $59.7 billion, marking a $700 million increase, which underscores its strong market position. The recent acquisitions of Cerevel and ImmunoGen further enhance AbbVie's product portfolio, solidifying its growth potential in key therapeutic areas like neuroscience and oncology.

Bears say

AbbVie faces significant downside risks, particularly concerning disappointing commercial execution across key assets like Skyrizi, Rinvoq, and Botox, as well as potential setbacks in clinical data and regulatory approvals for both marketed products and pipeline assets. The company's aesthetics business, which contributed approximately 9.2% to overall sales in FY 2024, is especially vulnerable to macroeconomic challenges and consumer spending volatility. Additionally, despite a slight EPS beat in 1Q 2025, higher-than-expected selling, general, and administrative (SG&A) and research and development (R&D) expenses continued to weigh on overall financial performance, raising concerns about cost management and sustainability.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 56% recommend Buy, 28% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.